Breakthrough Emactuzumab Phase 3 TANGENT Trial in TGCT: SynOx Pharma Reports Enrollment Completed Ahead of Schedule - OncoDaily SynOx Pharma completes Phase 3 TANGENT trial enrollment for Emactuzumab in TGCT, with top-line results expected in early 2026.

Breakthrough Emactuzumab Phase 3 TANGENT Trial in TGCT: SynOx Pharma Reports Enrollment Completed Ahead of Schedule

@synox-tx.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Emactuzumab #TANGENT #TGCT #SynOx

What the hell is #synox ?

I’ll be announcing a project called #SYNOX stay tuned !

SynOx Chair Transition Marks Growth Phase

Excited to welcome Philip Astley-Sparke to SynOx Tx. With our Phase 3 program well underway, a strengthened U.S. presence, and growing momentum, we’re entering a time of real possibility. Focused always on the patients we serve.
#tgct #pvns #synox

I will be announcing a new project on my page #synox coming soon !

Rare Disease Month @liferaftgroup.bsky.social #TGCT #LifeRaftGroup #SynOx